Arrowhead describes new RNAi delivery vehicle; FDA delays oral disintegrating tablet for ADHD;

> RNAi specialist Arrowhead discussed new enhancements to the company's RNAi drug delivery platform, including a new proprietary subcutaneous delivery vehicle, at the meeting of the Oligonucleotide Therapeutics Society in the Netherlands. More

> The FDA had identified deficiencies with Neos Therapeutics' extended-release oral disintegrating tablet for ADHD during a review of the candidate's New Drug Application. More